Since two groundbreaking treatments were approved in late 2023, only a handful of patients have been able to access the ...

Shares of CRISPR Therapeutics CRSP have lost more than 30% in the past year. Though the stock soared at the onset of 2024, ...

Lehigh University bioenginering researcher Tomas Gonzalez-Fernandez recently secured funding through the National Science ...

CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-based medicines with a market capitalization of $3.45 billion, stands at a critical juncture as it navigates ...

The "CRISPR-based Gene Editing Market by Product & Service, by Application, by End-User, and By Region" report has been added ...

A look at Intellia Therapeutics, Inc. and Editas Medicine, Inc., including their restructuring and pipeline prioritization.

Treatments for rare diseases are hard to create and expensive to deliver, but there is new hope for editing the software of ...

ECRC researchers developed a CRISPR-based gene therapy targeting dysferlin mutations in muscular dystrophy. By editing and ...

The three-year partnership is another example of Vertex’s interest in improving on Casgevy, its CRISPR medicine for sickle ...

Researchers at the Experimental and Clinical Research Center in Berlin are developing a targeted treatment for muscular ...

Ongoing launch of CASGEVY® continues to gain momentum--2025 is poised to be a catalyst-rich year with key updates across several ...

The science has proven that gene therapies are effective treatments, and they have given hope to patients and their families ...